SG11201703397UA - Methods and compositions for natural killer cells - Google Patents

Methods and compositions for natural killer cells

Info

Publication number
SG11201703397UA
SG11201703397UA SG11201703397UA SG11201703397UA SG11201703397UA SG 11201703397U A SG11201703397U A SG 11201703397UA SG 11201703397U A SG11201703397U A SG 11201703397UA SG 11201703397U A SG11201703397U A SG 11201703397UA SG 11201703397U A SG11201703397U A SG 11201703397UA
Authority
SG
Singapore
Prior art keywords
compositions
methods
natural killer
killer cells
cells
Prior art date
Application number
SG11201703397UA
Inventor
Alicja J Copik
Jeremiah L Oyer
Robert Y Igarashi
Deborah Altomare
Original Assignee
Univ Central Florida Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Central Florida Res Found filed Critical Univ Central Florida Res Found
Publication of SG11201703397UA publication Critical patent/SG11201703397UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201703397UA 2014-10-27 2015-10-27 Methods and compositions for natural killer cells SG11201703397UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462069057P 2014-10-27 2014-10-27
PCT/US2015/057591 WO2016069607A1 (en) 2014-10-27 2015-10-27 Methods and compositions for natural killer cells

Publications (1)

Publication Number Publication Date
SG11201703397UA true SG11201703397UA (en) 2017-05-30

Family

ID=55858255

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703397UA SG11201703397UA (en) 2014-10-27 2015-10-27 Methods and compositions for natural killer cells

Country Status (11)

Country Link
US (2) US11260076B2 (en)
EP (1) EP3223856A4 (en)
JP (3) JP7049830B2 (en)
CN (2) CN107206100B (en)
AU (2) AU2015339447B2 (en)
BR (1) BR112017008696A2 (en)
CA (1) CA2965952A1 (en)
HK (1) HK1245080A1 (en)
IL (2) IL294395A (en)
SG (1) SG11201703397UA (en)
WO (1) WO2016069607A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
SG11201903032SA (en) * 2016-10-05 2019-05-30 University Of Central Florida Research Foundation Inc Methods and compositions related to nk cell and anti-pdl1 cancer therapies
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
AU2018227801B2 (en) 2017-02-28 2024-02-22 Research Institute At Nationwide Children's Hospital PM21 particles to improve bone marrow homing of NK cells
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
JP7360704B2 (en) * 2017-05-05 2023-10-13 カプリコール，インコーポレイテッド Methods of treating systemic graft-versus-host disease using extracellular vesicles
CA3064897A1 (en) * 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
AU2018271755B2 (en) * 2017-05-26 2021-12-23 Green Cross Lab Cell Corporation Method for culturing natural killer cell, using transformed T cell
MX2020006672A (en) * 2017-12-28 2020-08-31 Codiak Biosciences Inc Exosomes for immuno-oncology and anti-inflammatory therapy.
CN109467607B (en) * 2017-12-28 2020-10-30 北京泽勤生物医药有限公司 Acid-sensitive fusion peptide targeting tumor and application thereof
RU2020127722A (en) * 2018-01-30 2022-02-28 Рисёч Инститьют Эт Нэйшенвайд Чилдрен'С Хоспитал NATURAL KILLER CELLS RESISTANT TO TRANSFORMING GROWTH FACTOR BETA
WO2019165097A1 (en) * 2018-02-21 2019-08-29 Board Of Regents,The University Of Taxas System Universal antigen presenting cells and uses thereof
CN109294985B (en) 2018-10-25 2022-02-18 江苏普瑞康生物医药科技有限公司 Culture medium system for NK cell in-vitro amplification and NK cell in-vitro amplification method
EP3656851A1 (en) * 2018-11-23 2020-05-27 Technische Universität Dresden Artificial hla-positive feeder cell lines for nk cells and uses thereof
JP2022520810A (en) * 2019-02-14 2022-04-01 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル Use of stimulants to assay the efficacy of immune cells
BR112021015791A2 (en) * 2019-02-14 2021-10-05 Research Institute At Nationwide Children's Hospital USE OF PLASMA MEMBRANE PARTICLES, LIPOSOMES AND EXOSOMES TO TEST THE POWER OF IMMUNE CELLS
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
KR20200110576A (en) * 2019-03-15 2020-09-24 재단법인대구경북과학기술원 Immune cells based on cytokines and immunotherapy uses thereof
CN109846866A (en) * 2019-03-27 2019-06-07 中国科学院昆明植物研究所 Application of the ent kauranoid class compound Parvifoline AA in pharmacy
WO2021093881A1 (en) * 2019-11-14 2021-05-20 上海鑫湾生物科技有限公司 Composition for regulating immune response in acidic environment, and preparation method therefor and use thereof
CN110904052A (en) * 2019-12-30 2020-03-24 北京鼎成肽源生物技术有限公司 Culture method of SNK cells
EP4099984A4 (en) * 2020-02-05 2024-05-01 Diadem Biotherapeutics Inc Artificial synapses
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
CN112029722A (en) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 NK cell culture medium and application thereof
AU2022299551A1 (en) * 2021-06-23 2024-01-18 Editas Medicine, Inc. Engineered cells for therapy
WO2023147404A2 (en) * 2022-01-26 2023-08-03 Rutgers, The State University Of New Jersey Compositions and methods for expanding immune cells
CN114716566A (en) * 2022-02-22 2022-07-08 广东粤港澳大湾区国家纳米科技创新研究院 Fusion protein and application thereof in preparing tumor medicine
CN115058393B (en) * 2022-07-13 2024-05-24 北京鼎成肽源生物技术有限公司 Coated stimulus, culture kit and natural killer cell culture method
JP7220938B1 (en) * 2022-09-28 2023-02-13 パナジー株式会社 Microparticles, NK cell activator, method for culturing NK cells, method for producing activated NK cells, and method for activating NK cells
CN115521914B (en) * 2022-10-12 2024-04-19 西北工业大学 In-vitro amplification system and method for human primary natural killer cells
CN116676265B (en) * 2023-04-18 2024-05-24 河南中医药大学第一附属医院 Acid-sensitive fusion peptide targeted exosome and preparation method and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624824A (en) 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
ATE140482T1 (en) 1992-04-28 1996-08-15 Univ Yale TARGETED CLEAVAGE OF RNA USING EUKARYONTIC RNASE P AND EXTERNAL GUIDING SEQUENCE
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5683873A (en) 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US5877162A (en) 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2827872A1 (en) 2001-07-30 2003-01-31 Roussy Inst Gustave In vitro preparation of membrane vesicles, useful for treatment of cancer and to induce immunological tolerance, from sample of mammalian body fluid
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
US20130058921A1 (en) * 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
CN102559600A (en) * 2011-12-29 2012-07-11 上海交通大学医学院 Artificial antigen presenting cell and application thereof in NK (natural killer) cell amplification
CN102586185A (en) * 2012-03-12 2012-07-18 浙江中赢方舟生物工程股份有限公司 Method for amplifying and activating NK (Natural Killer) cells by K562 cells
SG11201408697QA (en) * 2012-06-28 2015-02-27 Univ Central Florida Res Found Methods and compositions for natural killer cells
WO2014089029A1 (en) 2012-12-03 2014-06-12 Ohio State Innovation Foundation Activation of innate immunity by mirna for cancer and infection treatment
CN103484429A (en) * 2013-09-28 2014-01-01 青岛麦迪赛斯生物科技有限公司 Method for preparing NK (natural killer) cell

Also Published As

Publication number Publication date
JP2017532353A (en) 2017-11-02
US11260076B2 (en) 2022-03-01
US20170333479A1 (en) 2017-11-23
AU2021266360A1 (en) 2021-12-09
IL251951B (en) 2022-07-01
EP3223856A1 (en) 2017-10-04
EP3223856A4 (en) 2018-05-02
CN113151167A (en) 2021-07-23
AU2015339447A1 (en) 2017-05-25
CN107206100A (en) 2017-09-26
JP2022043068A (en) 2022-03-15
BR112017008696A2 (en) 2017-12-26
IL294395A (en) 2022-08-01
IL251951A0 (en) 2017-06-29
JP7049830B2 (en) 2022-04-07
CA2965952A1 (en) 2016-05-06
WO2016069607A1 (en) 2016-05-06
US20220143092A1 (en) 2022-05-12
AU2015339447B2 (en) 2021-08-12
JP2024028718A (en) 2024-03-05
CN107206100B (en) 2021-02-12
HK1245080A1 (en) 2018-08-24

Similar Documents

Publication Publication Date Title
HK1245080A1 (en) Methods and compositions for natural killer cells
HK1243333A1 (en) Methods and compositions for modified t cells
IL253248A0 (en) Natural killer cells and uses thereof
HK1244826A1 (en) Methods and compositions for adoptive cell therapy
HK1244841A1 (en) Methods and compositions for selectively eliminating cells of interest
IL251576A0 (en) Methods and compositions for generating or maintaining pluripotent cells
IL258666A (en) Natural killer cells and ilc3 cells and uses thereof
GB2535253B (en) Compositions and methods
SG11201609118RA (en) Modified natural killer cells and uses thereof
ZA201608378B (en) Improved t cell compositions
EP3215139A4 (en) Compositions and methods for improved car-t cell therapies
GB201417828D0 (en) New methods and compositions
IL246879B (en) Apilimod compositions and methods for using same
HUE057737T2 (en) Stem cell stimulating compositions and methods
SG11201702475VA (en) Methods and compositions for modulating th-gm cell function
SG11201701402QA (en) Anti-tumor compositions and methods
GB201402915D0 (en) Compositions and methods
EP3221366A4 (en) Polyaminomethylbenzyloxalamides and compositions and methods related thereto
GB201403212D0 (en) Compositions and methods
GB201415759D0 (en) Accelerator compositions and methods